Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

Journal of Infectious Diseases

Volumn 208, Issue 3, 2013, Pages 512-519

  Maiga, Mamoudou ^a,e   Ammerman, Nicole C ^a,f   Maiga, Mariama C ^a   Tounkara, Anatole ^e   Siddiqui, Sophia ^b   Polis, Michael ^b   Murphy, Robert ^d   Bishai, William R ^a,c,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e and Technologies of Bamako   (Mali)

^f AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

Author keywords

cilomilast; cilostazol; mouse model; phosphodiesterase inhibitor; rolipram; sildenafil; tuberculosis

Indexed keywords

CILOMILAST; CILOSTAZOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; ROLIPRAM; SILDENAFIL;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; HOST RANGE; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SHORT COURSE THERAPY; SURVIVAL TIME; TREATMENT DURATION;

CILOMILAST; CILOSTAZOL; MOUSE MODEL; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SILDENAFIL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; HUMANS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RIFAMPIN; ROLIPRAM; SULFONES; SURVIVAL ANALYSIS; TETRAZOLES; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84880229373     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit187     Document Type: Article

References (25)

1. World Health Organization (WHO). Treatment of tuberculosis: guidelines. 4th ed. Geneva, Switzerland: WHO Press, 2009.
2. World Health Organization (WHO). Report of the expert consultation on immunotherapeutic interventions for tuberculosis. Geneva, Switzerland: WHO Press, 2007.
3. Maiga M, Agarwal N, Ammerman NC, et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS One 2012; 7:e30749.
4. Koo MS, Manca C, Yang G, et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobac-terium tuberculosis in the lungs of infected mice. PLoS One 2011; 6: e17091.
5. Subbian S, Tsenova L, O'Brien P, et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 2011; 7: e1002262.
6. Subbian S, Tsenova L, O'Brien P, et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 2011; 179:289-301.
7. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100:309-27.
8. Dhillon J, Dickinson JM, Sole K, Mitchison DA. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifam-pin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40:552-5.
9. Harada D, Tsukumo Y, Takashima Y, Manabe H. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2, 4, 6-trinitro-1-chlorobenzene (TNCB)-repeated application. Eur J Pharmacol 2006; 532:128-37.
10. Xu H, Strassmann G, Chan CC, et al. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Invest Ophthalmol Vis Sci 1999; 40: 942-50.
11. Kobayashi M, Kubo S, Hirano Y, Kobayashi S, Takahashi K, Shimizu Y. Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor. Int Immunopharmacol 2012; 12:50-8.
12. Leclerc O, Lagente V, Planquois JM, et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 2006; 27:1102-9.
13. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4:e344.
14. Rosenthal IM, Tasneen R, Peloquin CA, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56: 4331-40.
15. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55:5485-92.
16. Michalski JM, Golden G, Ikari J, Rennard SI. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther 2012; 91:134-42.
17. Zhu J, Mix E, Winblad B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev 2001; 7:387-98.
18. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29:297-310.
19. Vats R, Varanasi KV, Arla R, Veeraraghvan S, Rajak S. Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats. Biopharm Drug Dispos 2012; 33:455-65.
20. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53(Suppl 1):5S-12.
21. Acocella G, Nonis A, Gialdroni-Grassi G, Grassi C. Comparative bioa-vailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study. Am Rev Respir Dis 1988; 138:882-5.
22. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999; 37(Suppl 2):1-11.
23. Savai R, Pullamsetti SS, Banat GA, et al. Targeting cancer with phos-phodiesterase inhibitors. Expert Opin Investig Drugs 2010; 19:117-31.
24. Marriott JB, Westby M, Cookson S, et al. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998; 161:4236-43.
25. Taegtmeyer A, Leuppi J, Kullak-Ublick G. Roflumilast-a phosphodies-terase-4 inhibitor licensed for add-on therapy in severe COPD. Swiss Med Wkly 2012; 142:w13628.